| 周 静,范震宇,倪 华,范裕兵,施向荣.曲妥珠单抗联合榄香烯注射液治疗乳腺癌的疗效及对血清BNP、cTnⅠ表达的影响[J].现代生物医学进展英文版,2022,(9):1770-1774. |
| 曲妥珠单抗联合榄香烯注射液治疗乳腺癌的疗效及对血清BNP、cTnⅠ表达的影响 |
| Effect of Trastuzumab Combined with Elemene Injection on the Expression of BNP and cTnⅠ in Serum of Breast Cancer |
| Received:October 04, 2021 Revised:October 27, 2021 |
| DOI：10.13241/j.cnki.pmb.2022.09.034 |
| 中文关键词: 曲妥珠单抗 榄香烯注射液 乳腺癌 血清BNP 血清cTnⅠ |
| 英文关键词: Trastuzumab Elemene injection Breast cancer Serum BNP and serum cTnⅠ |
| 基金项目:江苏省卫计委预防医学基金项目（Y2018038） |
|
| Hits: 745 |
| Download times: 385 |
| 中文摘要: |
| 摘要 目的：探究曲妥珠单抗联合榄香烯注射液治疗乳腺癌的疗效及对血清BNP、cTnⅠ表达的影响。方法：2018年2月至2021年6月于我院接受治疗的78例乳腺癌患者，将其按照治疗药物的不同分为观察组（39例）与对照组（39例），观察组给予曲妥珠单抗联合榄香烯注射液治疗，对照组仅给予曲妥珠单抗注射液治疗，对比两组患者治疗效果、术前术后T淋巴细胞亚群水平、生活质量、毒性反应、血清脑利钠肽（BNP）和高敏心肌肌钙蛋白（cTnⅠ）水平情况。结果：（1）观察组治疗总有效率较对照组高（P<0.05）；（2）观察组毒性反应总发生率为15.38 %显著低于对照组的35.90 %（P<0.05）；（3）治疗后观察组的CD3+、CD4+水平均较对照组高，CD8+水平较对照组低（P<0.05）；（4）治疗后血清cTnⅠ、BNP水平逐渐升高，且每一周期对照组血清cTnⅠ水平高于观察组（P<0.05）。（5）治疗后观察组躯体功能、认知功能、总体健康状况评分显著高于对照组（P<0.05）。结论：曲妥珠单抗联合榄香烯注射液治疗乳腺癌的可行性较好，能显著提高治疗有效率，改善患者的生活质量和免疫功能，同时还能降低血清BNP和cTnⅠ水平，值得临床推广应用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of trastuzumab combined with elemene injection on the expression of BNP and cTnⅠ in serum of breast cancer. Methods: 78 breast cancer patients treated in our hospital from February 2018 to June 2021 were divided into observation group (n=39) and control group (n=39) according to different treatment drugs. The observation group was treated with trastuzumab combined with elemene injection, and the control group was treated with trastuzumab injection only. The therapeutic effect, preoperative and postoperative T-lymphocyte subsets, quality of life, toxic reactions, serum BNP and cTnⅠ levels were compared between the two groups. Results: (1) The total effective rate of observation group was higher than that of control group (P<0.05). (2) The total incidence of toxicity in observation group was 15.38 %, significantly lower than 35.90 % in control group (P<0.05). (3) After treatment, CD3+ and CD4+ levels in the observation group were higher than those in the control group (P<0.05), while CD8+ levels were lower than those in the control group (P<0.05). (4) After treatment, the serum BNP and cTnⅠ levels increased gradually with the prolongation of treatment cycle, and the serum BNP and cTnⅠ levels in control group were increased compared with observation group in the same cycle (P<0.05). (5) After treatment, the scores of physical function, cognitive function and overall health status in observation group were higher than those in control group(P<0.05). Conclusion: The feasibility of trastuzumab combined with elemene injection in the treatment of breast cancer is good, which can significantly improve the treatment efficiency, improve the quality of life and immune function of patients, and reduce the serum BNP and cTnⅠ levels, which is worthy of clinical application. |
|
View Full Text
View/Add Comment Download reader |
| Close |
